BTG’s Ekos device targets pulmonary embolism with drug, ultrasound wave combo therapy

Each year, pulmonary embolisms kill more people in the U.S. than AIDs and breast cancer combined, according to BTG (LON:BTG). Venous clots in the legs or arm break off and travel through a patient’s circulatory system, eventually getting trapped in the lung and blocking the flow of blood.

In some cases, this strains the heart’s ability to pump blood through the lungs and ultimately leads to heart failure. Patients suffering from a pulmonary embolism tend to fall on a spectrum, BTG’s interventional vascular marketing VP Anastasia Mironova told Drug Delivery Business News, and that is part of what makes the condition so difficult to treat.

“One of the difficulties is that there are different kinds of patients within the pulmonary embolism population,” she said.

Get the full story at our sister site, Drug Delivery Business News.

The post BTG’s Ekos device targets pulmonary embolism with drug, ultrasound wave combo therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2n1ml3Y